HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
Health OTC Drugs Launches

Infirst Launches GSL Version Of Flarin Lipid Ibuprofen In UK

  • News

Executive Summary

Consumers in the UK can now self-select a version of Infirst's lipid-driven ibuprofen Flarin brand. 

You may also be interested in...



Infirst’s Flarin Lipid Ibuprofen Trialled As COVID-19 Treatment

A clinical trial will explore the effectiveness of OTC ibuprofen drug Flarin in reducing COVID-19 related respiratory failure in hospitalized patients, following "compelling" pre-clinical data.

David Vs Goliath – Flarin’s Macmillen On Slugging It Out With The Heavyweights

HBW Insight Exclusive: Flarin boss Andrew Macmillen on competing with the big OTC incumbents as a lean, innovation-focused company.

Building Trust In Brands Should Be A Continuous Process For The Self-Care Industry

“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Manoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”

Table

View full table

Topics

Tags:
Health OTC Drugs Launches
UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By